PMID- 24328511
OWN - NLM
STAT- MEDLINE
DCOM- 20141112
LR  - 20190318
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 3
DP  - 2014 Feb
TI  - The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and 
      dinner, and effects of the mitiglinide/voglibose fixed-dose combination on 
      postprandial profiles in Japanese patients with type 2 diabetes mellitus.
PG  - 311-24
LID - 10.1517/14656566.2014.868437 [doi]
AB  - BACKGROUND: Meal tolerance tests (MTTs) are usually conducted at breakfast after 
      overnight fasting in type 2 diabetes mellitus (T2DM) patients, but differences in 
      postprandial glycemic responses between meals have been reported. OBJECTIVE: We 
      conducted MTTs at breakfast, lunch, and dinner to examine the effects of a fixed 
      combination of 10 mg mitiglinide/0.2 mg voglibose (the combination) on 
      glycemic/metabolic responses to meals during the day in T2DM patients. MTTs with 
      unified meals were conducted in 11 T2DM patients before and after 4 weeks of 
      treatment with the combination administered thrice daily before meals. 
      Glycemic/metabolic profiles measured before and at 30, 60, and 120 min after each 
      meal were compared between each meal and between the baseline and treatment 
      periods. RESULTS AND CONCLUSION: The combination significantly reduced 
      postprandial hyperglycemia after each meal. Postprandial AUC0 - 120 min for 
      insulin significantly decreased after lunch and dinner compared with after 
      breakfast, while insulin levels significantly increased at only 30 min after 
      breakfast and dinner. The combination also significantly increased postprandial 
      C-peptide and active glucagon-like peptide-1 levels, and reduced free fatty acid 
      and triglyceride levels, but did not significantly affect glucagon levels 
      compared with baseline, confirming that treatment with the combination improves 
      postprandial responses in Japanese T2DM patients.
FAU - Ono, Yuri
AU  - Ono Y
AD  - Yuri Ono Clinic, Diabetes, Internal Medicine , Sapporo Kita-1 Ekimaedori Building 
      7F, 3-27, Nishi-3, Kita-1, Chuo-Ku, Sapporo 060-0001 , Japan +81 11 223 5152 ; 
      +81 11 223 5153 ; yuriono@ja2.so-net.ne.jp.
FAU - Nakamura, Akinobu
AU  - Nakamura A
FAU - Cho, Kyu Yong
AU  - Cho KY
FAU - Nomoto, Hiroshi
AU  - Nomoto H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131213
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Drug Combinations)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Isoindoles)
RN  - 0 (Triglycerides)
RN  - 4L6452S749 (Inositol)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9007-92-5 (Glucagon)
RN  - D86I0XLB13 (mitiglinide)
RN  - S77P977AG8 (voglibose)
SB  - IM
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Breakfast
MH  - C-Reactive Protein/analysis
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Combinations
MH  - Fatty Acids, Nonesterified/blood
MH  - Female
MH  - Glucagon/blood
MH  - Glucagon-Like Peptide 1/blood
MH  - Humans
MH  - Hyperglycemia/blood/drug therapy
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Inositol/*analogs & derivatives/therapeutic use
MH  - Insulin/blood
MH  - Isoindoles/*therapeutic use
MH  - Lunch
MH  - Male
MH  - *Meals
MH  - Middle Aged
MH  - *Postprandial Period
MH  - Triglycerides/blood
EDAT- 2013/12/18 06:00
MHDA- 2014/11/13 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2014/11/13 06:00 [medline]
AID - 10.1517/14656566.2014.868437 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Feb;15(3):311-24. doi: 
      10.1517/14656566.2014.868437. Epub 2013 Dec 13.